TY - JOUR
T1 - A comprehensive framework for navigating patient care in systemic sclerosis
T2 - A global response to the need for improving the practice of diagnostic and preventive strategies in SSc
AU - Saketkoo, Lesley Ann
AU - Frech, Tracy
AU - Varjú, Cecília
AU - Domsic, Robyn
AU - Farrell, Jessica
AU - Gordon, Jessica K.
AU - Mihai, Carina
AU - Sandorfi, Nora
AU - Shapiro, Lee
AU - Poole, Janet
AU - Volkmann, Elizabeth R.
AU - Lammi, Monika
AU - McAnally, Kendra
AU - Alexanderson, Helene
AU - Pettersson, Henrik
AU - Hant, Faye
AU - Kuwana, Masataka
AU - Shah, Ami A.
AU - Smith, Vanessa
AU - Hsu, Vivien
AU - Kowal-Bielecka, Otylia
AU - Assassi, Shervin
AU - Cutolo, Maurizio
AU - Kayser, Cristiane
AU - Shanmugam, Victoria K.
AU - Vonk, Madelon C.
AU - Fligelstone, Kim
AU - Baldwin, Nancy
AU - Connolly, Kerri
AU - Ronnow, Anneliese
AU - Toth, Beata
AU - Suave, Maureen
AU - Farrington, Sue
AU - Bernstein, Elana J.
AU - Crofford, Leslie J.
AU - Czirják, László
AU - Jensen, Kelly
AU - Hinchclif, Monique
AU - Hudson, Marie
AU - Lammi, Matthew R.
AU - Mansour, Jennifer
AU - Morgan, Nadia D.
AU - Mendoza, Fabian
AU - Nikpour, Mandana
AU - Pauling, John
AU - Riemekasten, Gabriela
AU - Russell, Anne Marie
AU - Scholand, Mary Beth
AU - Seigart, Elise
AU - Rodriguez-Reyna, Tatiana Sofia
AU - Hummers, Laura
AU - Walker, Ulrich
AU - Steen, Virginia
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/9
Y1 - 2021/9
N2 - Systemic sclerosis (SSc), the most lethal of rheumatologic conditions, is the cause of death in >50% of SSc cases, led by pulmonary fibrosis followed by pulmonary hypertension and then scleroderma renal crisis (SRC). Multiple other preventable and treatable SSc-related vascular, cardiac, gastrointestinal, nutritional and musculoskeletal complications can lead to disability and death. Vascular injury with subsequent inflammation transforming to irreversible fibrosis and permanent damage characterizes SSc. Organ involvement is often present early in the disease course of SSc, but requires careful history-taking and vigilance in screening to detect. Inflammation is potentially reversible provided that treatment intensity quells inflammation and other immune mechanisms. In any SSc phenotype, opportunities for early treatment are prone to be under-utilized, especially in slowly progressive phenotypes that, in contrast to severe progressive ILD, indolently accrue irreversible organ damage resulting in later-stage life-limiting complications such as pulmonary hypertension, cardiac involvement, and malnutrition. A single SSc patient visit often requires much more physician and staff time, organization, vigilance, and direct management for multiple organ systems compared to other rheumatic or pulmonary diseases. Efficiency and efficacy of comprehensive SSc care enlists trending of symptoms and bio-data. Financial sustainability of SSc care benefits from understanding insurance reimbursement and health system allocation policies for complex patients. Sharing care between recognised SSc centers and local cardiology/pulmonary/rheumatology/gastroenterology colleagues may prevent complications and poor outcomes, while providing support to local specialists. As scleroderma specialists, we offer a practical framework with tools to facilitate an optimal, comprehensive and sustainable approach to SSc care. Improved health outcomes in SSc relies upon recogntion, management and, to the extent possible, prevention of SSc and treatment-related complications.
AB - Systemic sclerosis (SSc), the most lethal of rheumatologic conditions, is the cause of death in >50% of SSc cases, led by pulmonary fibrosis followed by pulmonary hypertension and then scleroderma renal crisis (SRC). Multiple other preventable and treatable SSc-related vascular, cardiac, gastrointestinal, nutritional and musculoskeletal complications can lead to disability and death. Vascular injury with subsequent inflammation transforming to irreversible fibrosis and permanent damage characterizes SSc. Organ involvement is often present early in the disease course of SSc, but requires careful history-taking and vigilance in screening to detect. Inflammation is potentially reversible provided that treatment intensity quells inflammation and other immune mechanisms. In any SSc phenotype, opportunities for early treatment are prone to be under-utilized, especially in slowly progressive phenotypes that, in contrast to severe progressive ILD, indolently accrue irreversible organ damage resulting in later-stage life-limiting complications such as pulmonary hypertension, cardiac involvement, and malnutrition. A single SSc patient visit often requires much more physician and staff time, organization, vigilance, and direct management for multiple organ systems compared to other rheumatic or pulmonary diseases. Efficiency and efficacy of comprehensive SSc care enlists trending of symptoms and bio-data. Financial sustainability of SSc care benefits from understanding insurance reimbursement and health system allocation policies for complex patients. Sharing care between recognised SSc centers and local cardiology/pulmonary/rheumatology/gastroenterology colleagues may prevent complications and poor outcomes, while providing support to local specialists. As scleroderma specialists, we offer a practical framework with tools to facilitate an optimal, comprehensive and sustainable approach to SSc care. Improved health outcomes in SSc relies upon recogntion, management and, to the extent possible, prevention of SSc and treatment-related complications.
UR - http://www.scopus.com/inward/record.url?scp=85115619011&partnerID=8YFLogxK
U2 - 10.1016/j.berh.2021.101707
DO - 10.1016/j.berh.2021.101707
M3 - Scientific review articles
C2 - 34538573
AN - SCOPUS:85115619011
SN - 1521-6942
VL - 35
JO - Best Practice and Research: Clinical Rheumatology
JF - Best Practice and Research: Clinical Rheumatology
IS - 3
M1 - 101707
ER -